Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

BMC Cancer

Table 1 Patient characteristics according to total pathological complete response

	Non-pCR (n = 168)	pCR (n = 185)	All (n = 353)	P-value
Age (years), mean ± SD	49.39 ± 10.20	48.54 ± 9.92	48.94 ± 10.04	0.427
Tumor stage
cT1-2	107	129	236	0.320
cT3-4	61	56	117	0.320
Lymph node status
Negative	23	35	58	0.186
Positive	145	150	295	0.186
ER status
Negative	72	128	200	< 0.001
Positive	96	57	153	< 0.001
PR status
Negative	114	166	280	< 0.001
Positive	54	19	73	< 0.001
Histological Grade
I-II	97	92	189	0.132
III	71	93	164
Ki-67 index
< 30%	21	9	30	0.010
≥ 30%	147	176	323	0.010
HER2 status
2 +	43	13	56	< 0.001
3 +	125	172	297	< 0.001
IMPC
With	22	0	22	< 0.001
Without	146	185	331	< 0.001
Chemotherapy regimens
THP*4	57	46	103	0.077
TCbHP*6	91	122	213
AC4-THP4	20	17	37

ISSN: 1471-2407